Welcome to our dedicated page for Aimfinity Investment I SEC filings (Ticker: AIMTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aimfinity Investment Corp. I filings document the regulatory record of a SPAC issuer, including 8-K material events, shareholder voting matters, redemption mechanics, governance actions, and capital-structure disclosures for its OTC-traded AIMTF security. The filings also cover SPAC security-structure topics associated with a blank-check company, including trust-account and public-share redemption provisions when addressed in formal disclosures.
Its SEC record includes periodic-reporting obligations and Form 12b-25 notices for delayed annual and quarterly reports, alongside material-event filings that record agreements, shareholder-meeting matters, operating and financial reporting, and other disclosures tied to the company’s SPAC status.
Aimfinity Investment Corp. I disclosed that it issued a $500 unsecured promissory note to I-Fa Chang, a manager of its sponsor’s LLC, to fund a monthly extension payment into the SPAC trust account. This payment allows Aimfinity to extend the deadline to complete its initial business combination by one month, from December 28, 2025 to January 28, 2026, representing the third of up to nine one‑month extensions authorized under a prior charter amendment.
Under an existing exchange agreement, the note’s outstanding balance will automatically convert into PubCo ordinary shares at $10.00 per share if the business combination between Aimfinity and Docter Inc. closes, unless repaid earlier. The note was issued under a private offering exemption from registration, and the company also furnished a press release announcing the new extension while reiterating extensive forward‑looking statement and transaction risk disclosures.
Aimfinity Investment Corp. I, a SPAC, reported net income of $117,673 for the nine months ended September 30, 2025, driven by $630,505 of interest on cash and investments in its trust account, which more than offset $512,832 of formation and operating costs. The trust account balance fell to $14,294,569 from $36,940,228 at year-end 2024, mainly after redeeming 1,996,522 Class A shares for a total of $23,778,577.
Outside the trust, cash was only $3,517 with a working capital deficit of $2,785,815, and management concluded that these conditions, together with the limited time left to complete a merger, raise substantial doubt about the company’s ability to continue as a going concern. The SPAC continues to pursue a business combination with Docter Inc., has amended its charter multiple times to extend its deadline (with deposits totaling $1,808,413 into the trust for extensions), and has converted $1,500,000 of sponsor loans into 150,000 private units while restructuring deferred underwriting fees into a mix of cash and stock payable at closing.
Aimfinity Investment Corp. I disclosed that shareholders approved changes to its charter that let the company extend the deadline to complete its initial business combination in one-month increments, up to nine months, to July 28, 2026, by depositing $500 into its trust account for each extension. The charter was also amended to remove the requirement that any business combination leave the company with at least $5,000,001 of net tangible assets.
On November 28, 2025, Aimfinity issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, to fund the first new monthly extension, moving the transaction deadline from November 28, 2025 to December 28, 2025. Upon closing of its proposed business combination with Docter Inc., any unpaid balance of this note will automatically convert into PubCo ordinary shares at a price of $10.00 per share.
Aimfinity Investment Corp. I reported shareholder approval of an amendment allowing extensions of its business combination deadline to October 28, 2025, with up to nine one‑month extensions to July 28, 2026 by depositing $500 per month. The company elected to extend to November 28, 2025 and deposited $500 into its trust account.
The company was informed that 572,989 Class A ordinary shares were tendered for redemption in connection with the extension process. In addition, 503,472 Class A ordinary shares remain subject to redemption upon the closing of the proposed business combination with Docter Inc., based on prior requests. The business combination had previously been approved at the March 27, 2025 meeting.
Aimfinity’s securities trade over-the-counter: units (AIMUF), new units (AIMTF), and Class 1 redeemable warrants (AIMWF), each warrant exercisable for one Class A ordinary share at an exercise price of $11.50.
Aimfinity Investment Corp. I reported shareholder approval of two charter amendments to keep its SPAC process moving. The extension amendment lets the company extend its business combination deadline by up to nine one‑month periods to July 28, 2026, with a deposit of $500 into the trust account for each extension. The NTA amendment removes the prior requirement to maintain net tangible assets of at least $5,000,001 in connection with redemptions or closing.
To fund the first extension from October 28, 2025 to November 28, 2025, the company issued a $500 unsecured promissory note to the sponsor’s designee, exchangeable at closing of the Docter Inc. business combination into PubCo ordinary shares at $10.00 per share. The extension proposal passed with 2,785,849 votes for, 2,097 against, 4 abstain; the NTA change passed with 2,787,946 for, 0 against, 4 abstain. As of September 29, 2025, shares outstanding were 1,758,476 Class A and 2,012,500 Class B.
Aimfinity Investment Corp. I filed an 8-K to supplement its proxy materials for the Extraordinary Meeting. The company extended the deadline for public shareholders to submit redemption requests or reversals from October 23, 2025, 5:00 p.m. ET to October 27, 2025, 11:00 a.m. ET.
The filing clarifies that holders who previously elected to redeem in connection with the Docter Business Combination must reverse or withdraw that prior request and then submit a new redemption election for this Extraordinary Meeting if they wish to redeem now. It also notes there is no assurance the meeting will be held if the Docter Business Combination is completed beforehand; any proposed closing date will be announced at least 2 business days in advance.
Meeting logistics are unchanged: the session remains on October 27, 2025 at the Taiwan location with virtual access. The record date remains September 29, 2025.
Aimfinity Investment Corp. I filed its 10-Q showing modest non-operating profits and significant balance sheet changes typical of a SPAC nearing its deadline. For the six months ended June 30, 2025, the company reported net income of $75,425, driven by $484,941 of interest on trust assets and $409,516 of formation and operating costs. For Q2, net income was $10,494.
Trust assets were $13,981,534 as of June 30, 2025, after the redemption of 1,996,522 Class A shares for $23,778,577. 1,116,476 ordinary shares were classified as redeemable at $12.52 each. Working capital showed a deficit of $2,515,028, and management disclosed “substantial doubt” about continuing as a going concern absent a business combination by the extended deadline.
The company continues to pursue its merger with Docter Inc. It converted $1,500,000 of sponsor loans into 150,000 private units on April 8, 2025, and restructured deferred IPO underwriting fees on June 13, 2025 to $80,000 cash plus 132,875 PubCo shares for each underwriter at closing. Extensions funded through deposits push the combination window to October 28, 2025.
Aimfinity Investment Corp. I called an extraordinary general meeting for October 27, 2025 to vote on three items: extending its deadline to complete the Docter Business Combination and permitting up to nine one‑month extensions to July 28, 2026; removing the $5,000,001 net tangible asset redemption floor; and a potential adjournment to gather more votes.
If the extension is approved, the Sponsor would deposit $500 into the trust for each monthly extension. As of the September 29, 2025 record date, the trust held approximately $14.29 million. The company estimates a redemption price of about $12.80 per share, subject to the trust’s actual value at redemption. Shareholders may redeem by submitting New Units; the Class 2 warrants attached to redeemed New Units will be forfeited.
Approval of the two amendments requires a two‑thirds special resolution of Class A and Class B shares voting together. If the extension is not approved and no business combination is completed by October 28, 2025, the company states it will redeem public shares and liquidate.
Aimfinity Investment Corp. I is changing how it will acquire Inkrock Holding Limited in connection with its planned business combination with Docter Inc. The company and related parties terminated a prior May 27, 2025 securities purchase agreement that would have transferred all of CEO I-Fa Chang’s Inkrock securities to PubCo in exchange for the immediate issuance of 687,054 ordinary shares.
Because that earlier transfer was never completed, the parties signed a termination agreement on October 6, 2025 and a new securities purchase agreement on October 7, 2025. Under the new arrangement, the same 687,054 ordinary shares will be issued to the seller, and all Inkrock securities will be transferred to PubCo, but both steps will occur simultaneously with the closing of the approved business combination, as an unregistered sale of equity securities.